Andrew Flyak
Affiliations: | 2012-2016 | Microbiology and Immunology | Vanderbilt University School of Medicine, Nashville, TN, United States |
Google:
"Andrew Flyak"Parents
Sign in to add mentor| James Earl Crowe, Jr. | grad student | 2012-2016 | Vanderbilt Medical School |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Ogega CO, Skinner NE, Schoenle MV, et al. (2024) Convergent evolution and targeting of diverse E2 epitopes by human broadly neutralizing antibodies are associated with HCV clearance. Immunity |
| Frumento N, Sinnis-Bourozikas A, Paul HT, et al. (2023) Neutralizing antibodies evolve to exploit vulnerable sites in the HCV envelope glycoprotein E2 and mediate spontaneous clearance of infection. Immunity |
| Bozhanova NG, Flyak AI, Brown BP, et al. (2022) Computational identification of HCV neutralizing antibodies with a common HCDR3 disulfide bond motif in the antibody repertoires of infected individuals. Nature Communications. 13: 3178 |
| Frumento N, Figueroa A, Wang T, et al. (2022) Repeated exposure to heterologous hepatitis C viruses associates with enhanced neutralizing antibody breadth and potency. The Journal of Clinical Investigation |
| Ogega CO, Skinner NE, Flyak AI, et al. (2022) B cell overexpression of FCRL5 and PD-1 is associated with low antibody titers in HCV infection. Plos Pathogens. 18: e1010179 |
| Weber T, Potthoff J, Bizu S, et al. (2021) Analysis of antibodies from HCV elite neutralizers identifies genetic determinants of broad neutralization. Immunity |
| Muecksch F, Weisblum Y, Barnes CO, et al. (2021) Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Immunity |
| Murin CD, Gilchuk P, Ilinykh PA, et al. (2021) Convergence of a common solution for broad ebolavirus neutralization by glycan cap-directed human antibodies. Cell Reports. 35: 108984 |
| Muecksch F, Weisblum Y, Barnes CO, et al. (2021) Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies. Biorxiv : the Preprint Server For Biology |
| Flyak AI, Ruiz SE, Salas J, et al. (2020) Author response: An ultralong CDRH2 in HCV neutralizing antibody demonstrates structural plasticity of antibodies against E2 glycoprotein Elife |